💸 The Tape

Canada’s number one premium producer just raised a small cheque from a strategic investor to light up its biggest greenhouse. In a market where demand has outrun supply for years, that is the cheapest growth available.

Rubicon Organics announced Monday that it closed a $3.0 million non-brokered private placement with Siwash Rock Investments, selling 6,666,667 shares at $0.45. No warrants, no finder’s fees, a four-month hold, and TSXV approval pending. The proceeds fund a Lighting Project at Pacifica, the company’s 125,000-square-foot hybrid greenhouse in Delta, B.C., with the remainder going to working capital.

The numbers attached to that project are the point. After the lighting upgrade, Pacifica alone is expected to produce 15,500 kilograms a year, roughly a 40 percent lift from where it sits today. Combined with Cascadia, the 47,500-square-foot indoor facility in Hope, B.C., Rubicon’s total capacity moves to about 20,000 kilograms by June 2027. That target existed before Monday; what changed is the timeline, which the company says has been pulled forward by about a year. Total output from existing assets rises 29 percent with no new licence, no new building, and no acquisition.

Where Rubicon sits in the Canadian landscape

Rubicon is small by share count and large by category position. On Hifyre data, it was the number one premium licensed producer in Canada in Q2 2026 with 6.8 percent of the premium segment, and number one for the first half. In premium flower, the category that anchors the business, it holds 9.7 percent national share, up nearly two points year over year. Premium pre-rolls are at 4.8 percent and premium vapes at 5.8 percent. Wildflower is the number two topical brand in the country with 30.1 percent share and the top-selling topical SKU.

The portfolio splits cleanly. 1964 Supply Co., named Brand of the Year at both the High Buds Club and Grow Up Industry Awards this year, drives 64 percent of revenue. Simply Bare Organics, the certified-organic flag the company was built on, contributes 25 percent. Wildflower adds 6 percent, and international, led by 1964’s April launch into the U.K. medical market, is at 4 percent and expected to reach about 10 percent of 2026 revenue. Rubicon has agreements in two international markets today and is targeting four by year-end, with roughly a third of international revenue coming from the U.K.

The financial scale behind those shares: Q2 2026 net revenue was a record $18.5 million, up 23 percent year over year, with $32.1 million for the first half. Adjusted EBITDA was $1.1 million, down from $1.4 million as Cascadia’s startup costs weighed. Gross margin before fair value adjustments was 30 percent, or about 36 percent excluding $1.2 million of pre-revenue Cascadia expense. CFO Glen Ibbott has said margin targets “start with a four,” with three automated pre-roll lines and in-house hydrocarbon extraction expected to help vape margins in early 2027.

That position matters in context. Canadian premium dollar sales are down year over year as the category consolidates, and CEO Margaret Brodie has said she expects only two to four true super-premium brands to survive. Rubicon is growing revenue and gaining share inside a shrinking pool, which is the definition of taking it from someone else.

Why this is the right move

The strategic logic rests on one sentence Brodie has repeated for years and repeated again Monday: demand for Rubicon’s premium flower “has consistently exceeded our supply capacity.” A business that sells everything it grows has one growth lever, and it is kilograms. Pacifica’s per-crop yields already rose about 20 percent year over year in the first half of 2026 on both existing and new genetics; supplemental lighting in a B.C. hybrid greenhouse attacks the winter trough directly, which is the highest-return capex a greenhouse operator can deploy.

The terms are clean for a company of this size. No warrants means no overhang, no fees means every dollar goes into the facility, and a single strategic buyer means a holder who presumably intends to stay. Siwash Rock’s Ted Reid called Rubicon “an important inflection point” and is joining the company alongside the capital. For a stock at 45 cents, raising growth money without a broker and without a discount structure is the difference between dilution that builds and dilution that bleeds.

It also addresses the one soft spot in the Q2 print. Rubicon ended June with $3.0 million in cash against $20.9 million of working capital and $2.6 million of first-half capex. Management acknowledged the expansion “will require some capital improvements” that were still being assessed. Monday’s raise is that assessment, sized to the project rather than to a war chest.

What to watch

Three things. First, Cascadia yields, which are still below target with a target date of year-end; the facility has CUMCS and IMC-G.A.P. certifications and produced about $0.5 million of initial revenue in Q2, but it is the 4,500 kilograms that gets Rubicon from 15,500 to 20,000. Second, the margin ramp into the forties, which depends on the lighting, the pre-roll automation and extraction all landing on schedule. Third, the international mix, since a premium Canadian brand selling into U.K. medical channels at ten percent of revenue is a meaningfully different business than one selling only into provincial boards.

Rubicon is not trying to be Organigram or Aurora, and it is not in the consolidation crosshairs this week. It is a category leader with a supply problem, and $3 million from a strategic buyer to fix the cheapest part of that problem is the kind of small, sensible capital allocation the sector has spent five years forgetting how to do.

📈 Dog Walkers

$GLAS ( ▼ 14.02% ) Speaks To The Market

In light of this, there is still much uncertainty around the share price, and investors should proceed with caution.

Glass House Brands released preliminary, unaudited third-quarter numbers Monday, and the headline and the fine print point in different directions. Revenue hit a record $56.8 million, up from $47.0 million in Q2 and $26.2 million a year ago on a recast basis excluding the deconsolidated retail unit. Biomass production set a record at roughly 317,000 pounds, and cost of production fell to about $110 per pound from $122 last quarter and $175 in Q1.

Then the price line. Average selling price dropped to $150 per pound from $211 in Q2, a 29 percent sequential decline, landing below last year’s $155. Gross margin compressed to 26 percent from 34 percent, which the company attributed to seasonally weak California pricing and a trim-heavy mix carried over from Q2. Operating cash flow was slightly negative at $0.4 million.

Cash rose to $39.7 million, but the increase came from the capital markets, not operations: $18 million through the at-the-market program at an average of $8.11 per share, plus $10 million from warrants. The company says it has now turned off the ATM and estimates about $39 million is needed to finish its improvement projects and reach cash-flow positive. That is nearly the entire balance.

Tucked into the same release, director John “Jay” Nichols Jr. resigned from the board. No reason was given and no disagreement was disclosed, which is the standard language, but an unscheduled board departure bundled with a preliminary print is the kind of pairing that invites questions on the call.

CEO Kyle Kazan framed the quarter as proof the farms can scale through “challenging pricing,” and Graham Farrar pointed to GACP certification as groundwork for export. Both may prove right. For now, the story is record pounds sold into a falling market, funded by shares sold into it.

📺 Trade To Black

DEA Pushes Back on Reopening Rescheduling Hearing | TTB Weekly Recap

• Rescheduling’s latest twist: opponents move to reopen the DEA hearing over a GAO report on missing written procedures; the DEA’s October 9 filing didn’t object to admitting the report but pushed back hard on further proceedings. Judge Julius gave the government until October 21 to respond, and the stay holds. Plus a proposed briefing schedule in the challenge to the April medical order, with final briefs due February 19, 2027.

• Canadian consolidation gets crowded: reports of merger talks between Organigram (NASDAQ: OGI) and Aurora (NASDAQ: ACB) land while Curaleaf (TSX: CURA) pursues Aurora with a hostile bid, and British American Tobacco (NYSE: BTI) sits on an Organigram stake.

• Europe in motion: Cronos (NASDAQ: CRON) buys Dutch grower CanAdelaar for €57.5 million as Village Farms (NASDAQ: VFF) scales Dutch cultivation through Leli Holland.

• Operators doing the work: Glass House (NYSE: GLAS) earns GACP certification, Canopy Growth (NASDAQ: CGC) adds EU-GMP at Smiths Falls, Tilray (NASDAQ: TLRY) brings testing in-house in Portugal, and Green Thumb (CSE: GTII) outpaces Florida’s market growth. The takeaway: the strongest names may be the ones improving operations while Washington sorts out its timeline.